Sfoglia per Autore
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells
2019-01-01 Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs
2019-01-01 Vitale C, Salvetti C, Griggio V, Scamuffa MC, Zamprogna G, Visentin A, Cassin R, Laurenti L, Murru R, Rivela P, Marchetti M, Gentile M, Pennese E, Reda G, Trentin L, Tedeschi A, Mauro FR, Foà R, Boccadoro M, Coscia M
Anticorpi monoclonali bispecifici nel trattamento del mieloma multiplo
2019-01-01 Mattia D'Agostino; Mario Boccadoro
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2019-01-01 Griggio V, Vitale C, Salvetti C, Mauro FR, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino
2019-01-01 Gian Maria Zaccaria, Daniela Drandi, Simona Caltagirone, Martina Ferrante, Marco Ghislieri, Daniela Barbero, Marina Ruggeri, Barbara Mantoan, Elisa Genuardi, Daniela Oddolo, Giuseppe Lia, Valentina Griggio, Pierpaola Fenoglio, Mattia D’Agostino, Candida Vitale, Marta Coscia, Benedetto Bruno, Stefania Oliva, Paola Omedè, Alessandra Larocca, Simone Ferrero, Mario Boccadoro
FLAI induction regimen in elderly patients with acute myeloid leukemia
2019-01-01 Cerrano M.; Candoni A.; Crisa E.; Dubbini M.V.; D'Ardia S.; Zannier M.E.; Boccadoro M.; Audisio E.; Bruno B.; Ferrero D.
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies
2019-01-01 D'Agostino M.; Bertamini L.; Oliva S.; Boccadoro M.; Gay F.
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis
2019-01-01 Bonello F.; Pulini S.; Ballanti S.; Gentile M.; Spada S.; Annibali O.; Omede P.; Ronconi S.; Cangialosi C.; Podda L.; Palmas A.; Malfitano A.; Rivoli G.; Belotti A.; Ciambelli F.; Vincelli I.D.; Cafro A.M.; Innao V.; Palumbo A.; Sonneveld P.; Spencer A.; Hajek R.; Boccadoro M.; Gay F.
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
2019-01-01 Saltarella I.; Morabito F.; Giuliani N.; Terragna C.; Omede P.; Palumbo A.; Bringhen S.; De Paoli L.; Martino E.; Larocca A.; Offidani M.; Patriarca F.; Nozzoli C.; Guglielmelli T.; Benevolo G.; Callea V.; Baldini L.; Grasso M.; Leonardi G.; Rizzo M.; Falcone A.P.; Gottardi D.; Montefusco V.; Musto P.; Petrucci M.T.; Dammacco F.; Boccadoro M.; Vacca A.; Ria R.
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
2019-01-01 Bringhen S.; Milan A.; D'Agostino M.; Ferri C.; Wasch R.; Gay F.; Larocca A.; Offidani M.; Zweegman S.; Terpos E.; Goldschmidt H.; Cavo M.; Ludwig H.; Driessen C.; Auner H.W.; Caers J.; Gramatzki M.; Dimopoulos M.A.; Boccadoro M.; Einsele H.; Sonneveld P.; Engelhardt M.
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma
2019-01-01 D'Agostino M.; Gazzera G.; Cetani G.; Bringhen S.; Boccadoro M.; Gay F.
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
2019-01-01 Plesner T.; Arkenau H.-T.; Gay F.; Minnema M.C.; Boccadoro M.; Moreau P.; Cavenagh J.; Perrot A.; Laubach J.P.; Krejcik J.; Ahmadi T.; de Boer C.; Chen D.; Chiu C.; Schecter J.M.; Richardson P.G.
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes.
2019-01-01 G.M. Zaccaria, S. Ferrero, S. Rosati, M. Ghislieri, E. Genuardi, A. Evangelista, R. Sandrone, C. Castagneri, D. Barbero, M. Lo Schirico, L. Arcaini, A. L. Molinari, F. Ballerini, A. Ferreri, P. Omedè, A. Zamò, G. Balestra, M. Boccadoro, S. Cortelazzo, M. Ladetto
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies
2019-01-01 Bringhen S.; Mina R.; Petrucci M.T.; Gaidano G.; Ballanti S.; Musto P.; Offidani M.; Spada S.; Benevolo G.; Ponticelli E.; Galieni P.; Cavo M.; Di Toritto T.C.; Di Raimondo F.; Montefusco V.; Palumbo A.; Boccadoro M.; Larocca A.
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives
2019-01-01 Marta Coscia, Candida Vitale, Marco Cerrano, Enrico Maffini, Luisa Giaccone, Mario Boccadoro, Benedetto Bruno
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
2019-01-01 Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2019-01-01 Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S.
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
2018-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2018-01-01 Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target
2018-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells | 2019 | Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta | |
| Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs | 2019 | Vitale C, Salvetti C, Griggio V, Scamuffa MC, Zamprogna G, Visentin A, Cassin R, Laurenti L, Murru R, Rivela P, Marchetti M, Gentile M, Pennese E, Reda G, Trentin L, Tedeschi A, Mauro FR, Foà R, Boccadoro M, Coscia M | |
| Anticorpi monoclonali bispecifici nel trattamento del mieloma multiplo | 2019 | Mattia D'Agostino; Mario Boccadoro | |
| Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2019 | Griggio V, Vitale C, Salvetti C, Mauro FR, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino | 2019 | Gian Maria Zaccaria, Daniela Drandi, Simona Caltagirone, Martina Ferrante, Marco Ghislieri, Daniela Barbero, Marina Ruggeri, Barbara Mantoan, Elisa Genuardi, Daniela Oddolo, Giuseppe Lia, Valentina Griggio, Pierpaola Fenoglio, Mattia D’Agostino, Candida Vitale, Marta Coscia, Benedetto Bruno, Stefania Oliva, Paola Omedè, Alessandra Larocca, Simone Ferrero, Mario Boccadoro | |
| FLAI induction regimen in elderly patients with acute myeloid leukemia | 2019 | Cerrano M.; Candoni A.; Crisa E.; Dubbini M.V.; D'Ardia S.; Zannier M.E.; Boccadoro M.; Audisio E.; Bruno B.; Ferrero D. | |
| Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies | 2019 | D'Agostino M.; Bertamini L.; Oliva S.; Boccadoro M.; Gay F. | |
| Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis | 2019 | Bonello F.; Pulini S.; Ballanti S.; Gentile M.; Spada S.; Annibali O.; Omede P.; Ronconi S.; Cangialosi C.; Podda L.; Palmas A.; Malfitano A.; Rivoli G.; Belotti A.; Ciambelli F.; Vincelli I.D.; Cafro A.M.; Innao V.; Palumbo A.; Sonneveld P.; Spencer A.; Hajek R.; Boccadoro M.; Gay F. | |
| Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial | 2019 | Saltarella I.; Morabito F.; Giuliani N.; Terragna C.; Omede P.; Palumbo A.; Bringhen S.; De Paoli L.; Martino E.; Larocca A.; Offidani M.; Patriarca F.; Nozzoli C.; Guglielmelli T.; Benevolo G.; Callea V.; Baldini L.; Grasso M.; Leonardi G.; Rizzo M.; Falcone A.P.; Gottardi D.; Montefusco V.; Musto P.; Petrucci M.T.; Dammacco F.; Boccadoro M.; Vacca A.; Ria R. | |
| Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension | 2019 | Bringhen S.; Milan A.; D'Agostino M.; Ferri C.; Wasch R.; Gay F.; Larocca A.; Offidani M.; Zweegman S.; Terpos E.; Goldschmidt H.; Cavo M.; Ludwig H.; Driessen C.; Auner H.W.; Caers J.; Gramatzki M.; Dimopoulos M.A.; Boccadoro M.; Einsele H.; Sonneveld P.; Engelhardt M. | |
| Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma | 2019 | D'Agostino M.; Gazzera G.; Cetani G.; Bringhen S.; Boccadoro M.; Gay F. | |
| Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study | 2019 | Plesner T.; Arkenau H.-T.; Gay F.; Minnema M.C.; Boccadoro M.; Moreau P.; Cavenagh J.; Perrot A.; Laubach J.P.; Krejcik J.; Ahmadi T.; de Boer C.; Chen D.; Chiu C.; Schecter J.M.; Richardson P.G. | |
| Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. | 2019 | G.M. Zaccaria, S. Ferrero, S. Rosati, M. Ghislieri, E. Genuardi, A. Evangelista, R. Sandrone, C. Castagneri, D. Barbero, M. Lo Schirico, L. Arcaini, A. L. Molinari, F. Ballerini, A. Ferreri, P. Omedè, A. Zamò, G. Balestra, M. Boccadoro, S. Cortelazzo, M. Ladetto | |
| Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies | 2019 | Bringhen S.; Mina R.; Petrucci M.T.; Gaidano G.; Ballanti S.; Musto P.; Offidani M.; Spada S.; Benevolo G.; Ponticelli E.; Galieni P.; Cavo M.; Di Toritto T.C.; Di Raimondo F.; Montefusco V.; Palumbo A.; Boccadoro M.; Larocca A. | |
| Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives | 2019 | Marta Coscia, Candida Vitale, Marco Cerrano, Enrico Maffini, Luisa Giaccone, Mario Boccadoro, Benedetto Bruno | |
| Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial | 2019 | Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra | |
| Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis | 2019 | Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S. | |
| SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE | 2018 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M | |
| Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2018 | Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
| Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target | 2018 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile